Pilot Study of Preoperative Combined Modality Treatment for Locally Advanced Operable Oesophageal Carcinoma: Toxicities and Long-term Outcome

Mukherjee, Somnath; Abraham, Jesty; Brewster, Alison; Hardwick, Richard; Havard, Timothy; Lewis, Wyn G.; Askill, C.; Manson, James; Williams, Geraint T.; Roberts, S. A.; Court, Jacquelyn; Crosby, Tom

doi:10.1016/j.clon.2005.12.009

Cited by 6 publications

(2 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Neoadjuvant chemoradiotherapy was given to 49 patients, who received two cycles of cisplatin (60 mg/m 2 ) with 225 mg/m 2 per day of infusional 5‐fluorouracil (5‐FU) before 45 Gy radiotherapy in 25 fractions over 5 weeks, concurrent with cisplatin (60 mg/m 2 ) every 3 weeks and continuous infusional 5‐FU (200 mg/m 2 daily). As part of a local trial, 16 patients also received paclitaxel for four cycles in addition to 5‐FU and cisplatin 14 . Radiotherapy was administered using a two‐phase technique, starting with parallel opposed fields followed by a three‐field, three‐dimensional plan.…”

Section: Methodsmentioning

confidence: 99%

Prevalence and outcome of esophagogastric anastomotic leak after esophagectomy in a UK regional cancer network

Escofet

Manjunath

Twine

et al. 2010

Diseases of the Esophagus

View full text Add to dashboard Cite

The aim of this study was to determine the contemporary prevalence, outcome, and survival after esophagogastric anastomotic leakage (EGAL) following esophagectomy by a regional upper gastrointestinal cancer network and to investigate etiological factors. Two hundred forty consecutive patients underwent esophagectomy over a 10-year period (median age 61 [31-79] years, 147 transthoracic and 93 transhiatal esophagectomy, 105 neoadjuvant chemotherapy, 49 chemoradiotherapy). The primary outcome measures were the development of EGAL and survival. Twenty patients developed EGAL (8.3%, 15 managed conservatively, 5 reoperation). Overall operative mortality was 2% (5 patients in total, 1 after EGAL). Median, 1 and 2-year survival was 22 months, 73% and 50%, in patients after EGAL, compared with 31 months, 80% and 56%, in patients who did not suffer EGAL (P= 0.314). On multivariate analysis, low body mass indices (hazard ratio [HR] 0.29, 95% confidence interval [CI] 0.11-0.79, P= 0.016), individual surgeon (HR 1.21, 95% CI 1.02-1.43, P= 0.02), and neoadjuvant chemotherapy (HR 3.28, 95% CI 1.16-9.22, P= 0.024) were significantly associated with the development of EGAL. EGAL following esophagectomy remained common, but associated mortality was less common than reported in earlier Western series and long-term survival was unaffected.

show abstract

Section: Methodsmentioning

confidence: 99%

Prevalence and outcome of esophagogastric anastomotic leak after esophagectomy in a UK regional cancer network

Escofet

Manjunath

Twine

et al. 2010

Diseases of the Esophagus

View full text Add to dashboard Cite

show abstract

“…Before 2002, patients were treated with neoadjuvant chemoradiotherapy involving two cycles of cisplatin (60 mg/m 2 ) and 225 mg/m 2 per day of infusional 5‐fluorouracil (5‐FU) before 45 Gy radiotherapy was administered in 25 fractions over 5 weeks concurrent with 60 mg/m 2 cisplatin every 3 weeks and 200 mg/m 2 infusional 5‐FU. A small number of these patients also received paclitaxel for four cycles in addition to cisplatin and 5‐FU. Radiotherapy was administered using a two‐phase technique, starting with parallel opposed fields followed by a three‐field, three‐dimensional plan.…”

Section: Methodsmentioning

confidence: 99%

Propensity score analysis of oesophageal cancer treatment with surgery or definitive chemoradiotherapy

Karran

Blake

Chan

et al. 2014

British Journal of Surgery

View full text Add to dashboard Cite

show abstract

Prospective cohort comparison of neoadjuvant chemoradiotherapy versus chemotherapy in patients with oesophageal cancer

Morgan

Lewis

Crosby

et al. 2007

British Journal of Surgery

View full text Add to dashboard Cite

show abstract

Pilot Study of Preoperative Combined Modality Treatment for Locally Advanced Operable Oesophageal Carcinoma: Toxicities and Long-term Outcome

Cited by 6 publications

References 25 publications

Prevalence and outcome of esophagogastric anastomotic leak after esophagectomy in a UK regional cancer network

Prevalence and outcome of esophagogastric anastomotic leak after esophagectomy in a UK regional cancer network

Propensity score analysis of oesophageal cancer treatment with surgery or definitive chemoradiotherapy

Prospective cohort comparison of neoadjuvant chemoradiotherapy versus chemotherapy in patients with oesophageal cancer

Contact Info

Product

Resources

About